Last checked at 
LONDON (Alliance News) - Sareum Holdings PLC shares were up Tuesday morning after the company said Chief Executive Tim Mitchell would describe the company's research pipeline, including the programme set to file for clinical trials later this year, at the BioTrinity event in London on May 12.
The specialist drug discovery and development business said the presentation will include the CHK1 cancer programme which is expected to file for clinical trials approval later this year.
BioTrinity is a biopartnering and investment conference.
"This exciting event offers us an ideal opportunity to present our latest developments to both investors and potential licence partners," Mitchell said in a statement.
Sareum shares were up 8.4% at 0.450 pence Tuesday morning.
By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1
Copyright 2015 Alliance News Limited. All Rights Reserved.
